|
|
Article: SCOLR Pharma Announces Worldwide Licensing Agreement with Wyeth Consumer Healthcare.
- Article from:
- Business Wire
- Article date:
- December 22, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BELLEVUE, Wash. -- SCOLR Pharma, Inc. (Amex: DDD) announced today that it has executed a Licensing Agreement with Wyeth Consumer Healthcare, a division of Wyeth (NYSE: WYE), granting Wyeth Consumer Healthcare the worldwide rights to utilize SCOLR Pharma's proprietary and patented CDT(R) drug delivery platform for the potential use in an over-the-counter (OTC) formulation. There is currently no formulation of this type approved for use in North America.
Under the terms of this Agreement, Wyeth Consumer Healthcare will pay SCOLR Pharma an upfront licensing fee, and will make milestone and royalty payments. The License Agreement also contemplates further ...
Related newspaper, magazine, and journal articles:
|
|
Article: SCOLR Pharma, Inc. Reports Third Quarter 2006 ...
Business Wire;
November 6, 2006 ;
700+ words
...BELLEVUE, Wash. -- SCOLR Pharma, Inc. (AMEX: DDD) today ... license agreement with Wyeth Consumer Healthcare, a division of Wyeth. Revenues ... development milestone with Wyeth Consumer Healthcare. SCOLR reported the milestone ...
|
|